文献速递肝病

非酒精性脂肪性肝炎的临床试验全景

Clinical Trial Landscape in NASH.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-04-12

非酒精性脂肪性肝炎(NASH)患病率随肥胖和2型糖尿病上升而增加,可进展为纤维化、肝硬化、肝细胞癌甚至肝衰竭。2A期研究评估多种作用机制,3期研究主要聚焦NASH和纤维化2期及以上患者。尽管多种药物失败,近期2期和3期研究显示有希望的结果,首个获美国食品药品监督管理局批准用于NASH的药物预计于2023年获批。本文综述NASH在研药物、作用机制及临床试验结果,并强调药物开发中的潜在挑战。

要点

  • NASH患病率随肥胖和2型糖尿病患病率上升而增加,可进展为纤维化、肝硬化、肝细胞癌甚至肝衰竭。
  • 2A期研究评估多种作用机制,3期研究主要聚焦NASH和纤维化2期及以上患者,因该人群疾病发病和死亡风险更高。
  • 早期试验采用无创检测作为主要疗效终点,3期研究按监管机构要求采用肝脏组织学终点。

核心结论

  • 尽管多种药物失败令人失望,近期2期和3期研究显示有希望的结果,首个获美国食品药品监督管理局批准用于NASH的药物预计于2023年获批。

研究设计与样本

  • 本文为综述,讨论NASH在研药物、作用机制及临床试验结果,并强调药物开发中的潜在挑战。

主要发现

  • 2A期研究评估多种作用机制,3期研究主要聚焦NASH和纤维化2期及以上患者,因该人群疾病发病和死亡风险更高。
  • 早期试验采用无创检测作为主要疗效终点,3期研究按监管机构要求采用肝脏组织学终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease consists of a spectrum starting from nonalcoholic fatty liver disease that may progress to nonalcoholic steatohepatitis (NASH), which can lead to fibrosis, cirrhosis, hepatocellular carcinoma, or even liver failure. The prevalence of NASH has increased in parallel with the rising rate of obesity and type 2 diabetes. Given the high prevalence and deadly complications of NASH, there have been significant efforts to develop effective treatments. Phase 2A studies have assessed various mechanisms of action across the spectrum of the disease, while phase 3 studies have focused mainly on NASH and fibrosis stage 2 and higher, as these patients have a higher risk of disease morbidity and mortality. The primary efficacy endpoints also vary, by using noninvasive tests in early-phase trials while relying on liver histological endpoints in phase 3 studies as required by regulatory agencies. Despite initial disappointment due to the failure of several drugs, recent phase 2 and 3 studies have shown promising results, with the first Food and Drug Administration-approved drug for NASH expected to be approved in 2023. In this review, we discuss the various drugs under development for NASH, their mechanisms of action, and the results of their clinical trials. We also highlight the potential challenges in developing pharmacological therapies for NASH.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Loomba R, Dubourg J, et al. Clinical Trial Landscape in NASH. Clin Gastroenterol Hepatol. 2023. PMID: 37059159. doi:10.1016/j.cgh.2023.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。